113 episodes

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

JAMA Oncology Author Interviews JAMA Network

    • Health & Fitness

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

    T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

    T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

    Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD.

    Related Content:
    T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

    • 19 min
    Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time

    Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time

    Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD.

    Related Content:
    Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time

    • 25 min
    Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer

    Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer

    Interview with José P. Leone, MD, author of Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. Hosted by Nora L. (Mary) Disis, MD.

    Related Content:
    Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer

    • 14 min
    Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US

    Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US

    Interview with Sajid A. Khan, MD, author of Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. Hosted by Mary L. (Nora) Disis, MD.

    Related Content:
    Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US

    • 17 min
    Atezolizumab in Combination With Carboplatin in Metastatic TNBC

    Atezolizumab in Combination With Carboplatin in Metastatic TNBC

    Interview with Jennifer A. Pietenpol, PhD, Brian D. Lehmann, PhD, and Vandana G. Abramson, MD, authors of Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. Hosted by Mary L. (Nora) Disis, MD.

    Related Content:
    Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

    • 18 min
    Shorter-Course Radiotherapy for Prostate Cancer

    Shorter-Course Radiotherapy for Prostate Cancer

    Interview with Daniel E. Spratt, MD, author of Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer. Hosted by Jack West, MD.

    Related Content:
    Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer

    • 15 min

Top Podcasts In Health & Fitness

HjerneRO
Mindcamp
ADHD Podcast med Manu Sareen
Manu Sareen, Podads
Vores Mentale Sundhed - En Mind Care Collective Podcast
Lea Hellmann
Psykologen i Øret
Birgitte Sølvstein
Detox Din Hjerne
Morten Elsøe & Anne Gaardmand
Huberman Lab
Scicomm Media

You Might Also Like

JAMA Editors' Summary
JAMA Network
JAMA Medical News
JAMA Network
NEJM This Week
NEJM Group
JAMA Clinical Reviews
JAMA Network
Plenary Session
Vinay Prasad, MD MPH
The Curious Clinicians
The Curious Clinicians

More by JAMA Network

JAMA Medical News
JAMA Network
JAMA Otolaryngology–Head & Neck Surgery Author Interviews
JAMA Network
JAMA Psychiatry Author Interviews
JAMA Network
JAMA Clinical Reviews
JAMA Network
JAMAevidence JAMA Guide to Statistics and Methods
JAMA Network
JAMA Surgery Editors' Summary
JAMA Network